公开(公告)号：US20220307022A1

公开(公告)日：2022-09-29

申请号：US17615520

申请日：2020-06-01

Applicant: AMGEN INC.

Inventor： Amrita DAS ,  Bradley J. HERBERICH ,  Justin K. MURRAY ,  Oliver HOMANN ,  Michael OLLMANN ,  Daniel C.H. LIN

IPC: C12N15/113 ,  A61K31/713 ,  A61K31/7105

Abstract: The present invention relates to RNAi constructs for reducing expression of the SCAP gene. Methods of using such RNAi constructs to treat or prevent liver disease, nonalcoholic fatty liver disease (NAFLD) are also described.

公开(公告)号：US20160008439A1

公开(公告)日：2016-01-14

申请号：US14772910

申请日：2014-03-13

Applicant: AMGEN INC.

Inventor： Daniel C.H. LIN ,  Jinghong WANG ,  Yang LI

IPC: A61K38/46 ,  A61B5/145 ,  C12N9/20

CPC classification number: A61K38/465 ,  A61B5/14532 ,  C12N9/20 ,  C12Y301/01004

Abstract: Methods of treating or ameliorating metabolic diseases using a PLA2G12A polypeptide or PLA2G12A mutant polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes mellitus, obesity, dyslipidemia elevated glucose levels, elevated insulin levels and diabetic nephropathy.

Abstract translation: 提供了使用PLA2G12A多肽或PLA2G12A突变体多肽治疗或改善代谢疾病的方法。 在各种实施方案中，代谢疾病或病症是2型糖尿病，肥胖症，血脂异常升高的葡萄糖水平，升高的胰岛素水平和糖尿病性肾病。